← Back to Clinical Trials
Recruiting NCT07029841

NCT07029841 Cohort Study on Treatment Comes of Catheter-based Therapy in Patients With Acute Pulmonary Embolism in Hong Kong

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07029841
Status Recruiting
Phase
Sponsor Chinese University of Hong Kong
Condition Pulmonary Embolism Acute
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2022-06-01
Primary Completion 2032-12-28

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
catheter-based therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2022-06-01 with a primary completion date of 2032-12-28.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This retrospective cohort study (Hong Kong PECT Registry) compares treatment outcomes between different percutaneous catheter-based therapies in patients with acute pulmonary embolism (PE). PE is a critical condition with potential for rapid deterioration and mortality before treatment. While availability of catheter-based therapy contributed to the declining mortality rates of PE, selecting the appropriate intervention remains key. There are primarily two modes of therapies available: Catheter-directed thrombolysis and Aspiration thrombectomy (e.g., Penumbra, Flowtriever, AlphaVac) Given limited direct comparisons between these methods, the study will evaluate their efficacy, safety, and clinical outcomes of these treatment strategies in acute PE patients.

Eligibility Criteria

Inclusion Criteria: * Patients who is admitted with a diagnosis of acute pulmonary embolism * Patient who receives any types of catheter-based therapy for acute pulmonary embolism. Exclusion Criteria: * nil. This is a all-comer registry.

Contact & Investigator

Central Contact

GuangMing Tan

✉ gtan@cuhk.edu.hk

📞 852 +55699658

Frequently Asked Questions

Who can join the NCT07029841 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Embolism Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07029841 currently recruiting?

Yes, NCT07029841 is actively recruiting participants. Contact the research team at gtan@cuhk.edu.hk for enrollment information.

Where is the NCT07029841 trial being conducted?

This trial is being conducted at Hong Kong, Hong Kong.

Who is sponsoring the NCT07029841 clinical trial?

NCT07029841 is sponsored by Chinese University of Hong Kong. The trial plans to enroll 1,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology